Persistent Therapeutic Effect of Repeated Injections of Onabotulinum Toxin A in Refractory Bladder Pain Syndrome/Interstitial Cystitis
- 1 February 2013
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 189 (2), 548-553
- https://doi.org/10.1016/j.juro.2012.09.027
Abstract
We evaluate the efficacy and safety of repeated intratrigonal injections of onabotulinum toxin A in patients with bladder pain syndrome/interstitial cystitis. This is a single center, long-term, prospective study in which 16 women with bladder pain syndrome/interstitial cystitis refractory to standard treatment received 4 consecutive intratrigonal injections of onabotulinum toxin A. Onabotulinum toxin A (100 U) was injected under cystoscopic control in 10 trigonal sites, each receiving 10 U in 1 ml saline. General anesthesia was used in all treatments. Re-treatment was allowed 3 months after injection. Outcome measures included pain visual analog scale (0-10), O'Leary-Sant score, a 3-day voiding chart and a quality of life questionnaire at the first month and every 3 months after each injection. Voiding dysfunction and urinary tract infections were assessed at 2 weeks and every 3 months afterward. Treatment duration was determined when patients requested another injection. Mean ± SD patient age was 41.8 ± 12.5 years. At baseline pain score was 5.9 ± 1.8, O'Leary-Sant score 28.8 ± 6.3, urinary frequency 16.4 ± 5.3, mean voided volume 112 ± 42 ml and quality of life 5 ± 0.9. Mean decrease in pain score, O'Leary-Sant score, urinary frequency and mean increase in voided volume and quality of life were similar after each treatment. Individual symptom relief lasted 6 to 12 months with an average duration of 9.9 ± 2.4 months. There were no cases of voiding dysfunction. Five patients had noncomplicated urinary tract infections. Symptomatic improvement of bladder pain syndrome/interstitial cystitis persists in a repeated intratrigonal injection program of 100 U onabotulinum toxin A. Time to request re-treatment remained stable. Adverse events were mild, without voiding dysfunction requiring intermittent catheterization.Keywords
This publication has 22 references indexed in Scilit:
- Botulinum Neurotoxin Serotype A Suppresses Neurotransmitter Release from Afferent as Well as Efferent Nerves in the Urinary BladderEuropean Urology, 2012
- Contemporary Management of the Painful Bladder: A Systematic ReviewEuropean Urology, 2012
- AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain SyndromeJournal of Urology, 2011
- Bladder Pain SyndromeMedical Clinics of North America, 2011
- Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndromeBJU International, 2009
- Recommendations on the Use of Botulinum Toxin in the Treatment of Lower Urinary Tract Disorders and Pelvic Floor Dysfunctions: A European Consensus ReportEuropean Urology, 2009
- Botulinum A Toxin Intravesical Injection in Patients With Painful Bladder Syndrome: 1-Year FollowupJournal of Urology, 2008
- Diagnostic Criteria, Classification, and Nomenclature for Painful Bladder Syndrome/Interstitial Cystitis: An ESSIC ProposalEuropean Urology, 2008
- Botulinum Toxin Type A Inhibits Calcitonin Gene-Related Peptide Release From Isolated Rat BladderJournal of Urology, 2006
- INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATSJournal of Urology, 2004